Salvage Androgen Deprivation Therapy As Potential Treatment for Recurrence After Robot-Assisted Radical Prostatectomy

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Apr 13

PMID 38610982

Authors

Hiroshi Kano

Yoshifumi Kadono

Renato Naito

Tomoyuki Makino

Hiroaki Iwamoto

Hiroshi Yaegashi

Shohei Kawaguchi

Takahiro Nohara

Kazuyoshi Shigehara

Kouji Izumi

Atsushi Mizokami

Affiliations

Soon will be listed here.

Abstract

Background: The efficacy of intermittent androgen deprivation therapy (ADT) for biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP) is unknown, and its usefulness in Japanese practice needs to be investigated.

Methods: We conducted a retrospective analysis of 85 patients who underwent RARP and were selected for intermittent ADT for postoperative recurrence at Kanazawa University Hospital between 2009 and 2019. Intermittent ADT was administered for 2 years. If prostate-specific antigen levels increased post-treatment, intermittent ADT was reinitiated. The median follow-up period was 47 months.

Results: The 73 patients had completed the initial course of ADT, and 12 were under initial ADT. The 5-year castration-resistant prostate-cancer-free survival rates, cancer-specific survival, and overall survival were 92.7%, 98.3%, and 94.7%, respectively. A subgroup analysis of 69 patients who completed intermittent ADT was conducted to evaluate the BCR rate following initial ADT. The 5-year BCR-free survival rate was 53.2%. Multivariate analysis identified testosterone ≤ 0.03 ng/mL during ADT as the sole predictor of BCR after ADT.

Conclusions: Salvage intermittent ADT may be an effective treatment option for BCR after RARP. In addition, it would be useful to confirm strong testosterone suppression as a criterion for transition to intermittent therapy.

References

Kano H, Izumi K, Nakagawa R, Toriumi R, Aoyama S, Kamijima T . Role of Positive Biopsy Core Ratio in Prostate Cancer Patients. Anticancer Res. 2023; 43(10):4619-4626. DOI: 10.21873/anticanres.16656. View

Siddiqui S, Boorjian S, Inman B, Bagniewski S, Bergstralh E, Blute M . Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol. 2008; 179(5):1830-7. DOI: 10.1016/j.juro.2008.01.022. View

Alibhai S, Duong-Hua M, Sutradhar R, Fleshner N, Warde P, Cheung A . Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009; 27(21):3452-8. PMC: 5233456. DOI: 10.1200/JCO.2008.20.0923. View

Fukagai T, Namiki T, Carlile R, Yoshida H, Namiki M . Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int. 2006; 97(6):1190-3. DOI: 10.1111/j.1464-410X.2006.06201.x. View

Shiota M, Akamatsu S, Narita S, Terada N, Fujimoto N, Eto M . Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer. JMA J. 2021; 4(2):99-111. PMC: 8119070. DOI: 10.31662/jmaj.2021-0004. View

Kano H, Izumi K, Hiratsuka K, Toriumi R, Nakagawa R, Aoyama S . Suppression of androgen receptor signaling induces prostate cancer migration via activation of the CCL20-CCR6 axis. Cancer Sci. 2022; 114(4):1479-1490. PMC: 10067408. DOI: 10.1111/cas.15683. View

van Dessel L, Reuvers S, Bangma C, Aluwini S . Salvage radiotherapy after radical prostatectomy: Long-term results of urinary incontinence, toxicity and treatment outcomes. Clin Transl Radiat Oncol. 2018; 11:26-32. PMC: 6019864. DOI: 10.1016/j.ctro.2018.05.001. View

Tsai H, Pfeiffer R, Philips G, Barac A, Fu A, Penson D . Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study. J Urol. 2016; 197(5):1251-1257. PMC: 5794210. DOI: 10.1016/j.juro.2016.12.022. View

Ghadjar P, Aebersold D, Albrecht C, Bohmer D, Flentje M, Ganswindt U . Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy. Strahlenther Onkol. 2018; 194(7):619-626. DOI: 10.1007/s00066-018-1269-3. View

10.

Trock B, Han M, Freedland S, Humphreys E, DeWeese T, Partin A . Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008; 299(23):2760-9. PMC: 3076799. DOI: 10.1001/jama.299.23.2760. View

11.

Akaza H . Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology. 2010; 85(2):110-20. DOI: 10.1159/000274486. View

12.

Salciccia S, Frisenda M, Tufano A, Di Pierro G, Bevilacqua G, Rosati D . Intermittent Versus Continuous Androgen Deprivation Therapy for Biochemical Progression After Primary Therapy in Hormone-Sensitive Nonmetastatic Prostate Cancer: Comparative Analysis in Terms of CRPC-M0 Progression. Clin Genitourin Cancer. 2023; 22(2):74-83. DOI: 10.1016/j.clgc.2023.08.008. View

13.

Cotter S, Chen M, Moul J, Lee W, Koontz B, Anscher M . Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011; 117(17):3925-32. DOI: 10.1002/cncr.25993. View

14.

Shibata Y, Suzuki K, Arai S, Miyoshi Y, Umemoto S, Masumori N . Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy. Andrology. 2013; 1(3):505-11. DOI: 10.1111/j.2047-2927.2013.00068.x. View

15.

Roder M, Brasso K, Christensen I, Johansen J, Langkilde N, Hvarness H . Survival after radical prostatectomy for clinically localised prostate cancer: a population-based study. BJU Int. 2013; 113(4):541-7. DOI: 10.1111/bju.12065. View

16.

Perera M, Roberts M, Klotz L, Higano C, Papa N, Sengupta S . Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. Nat Rev Urol. 2020; 17(8):469-481. DOI: 10.1038/s41585-020-0335-7. View

17.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

18.

Kano H, Kadono Y, Kadomoto S, Iwamoto H, Yaegashi H, Iijima M . Similar Recurrence Rate Between Gleason Score of Six at Positive Margin and Negative Margin After Radical Prostatectomy. Anticancer Res. 2021; 41(1):509-516. DOI: 10.21873/anticanres.14802. View

19.

Van den Broeck T, van den Bergh R, Arfi N, Gross T, Moris L, Briers E . Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2018; 75(6):967-987. DOI: 10.1016/j.eururo.2018.10.011. View

20.

Kim W, Kim J, Kim W . How can we best manage biochemical failure after radical prostatectomy?. Investig Clin Urol. 2022; 63(6):592-601. PMC: 9643724. DOI: 10.4111/icu.20220294. View